|
1
|
Biswal BK, Beyrouthy MJ, Hever-Jardine MP,
et al: Acute hypersensitivity of pluripotent testicular
cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine
is associated with global DNA damage-associated p53 activation,
anti-pluripotency and DNA demethylation. PLoS One. 7:e530032012.
View Article : Google Scholar
|
|
2
|
Coyle DE, Li J and Baccei M: Regional
differentiation of retinoic acid-induced human pluripotent
embryonic carcinoma stem cell neurons. PLoS One. 6:e161742011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Favaedi R, Shahhoseini M and Akhoond MR:
Comparative epigenetic analysis of Oct4 regulatory region in
RA-induced differentiated NT2 cells under adherent and non-adherent
culture conditions. Mol Cell Biochem. 363:129–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tegenge MA, Roloff F and Bicker G: Rapid
differentiation of human embryonal carcinoma stem cells (NT2) into
neurons for neurite outgrowth analysis. Cell Mol Neurobiol.
31:635–643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Drakulic D, Krstic A and Stevanovic M:
Establishment and initial characterization of SOX2-overexpressing
NT2/D1 cell clones. Genet Mol Res. 11:1385–1400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jezierski A, Deb-Rinker P, Sodja C, et al:
Involvement of NOS3 in RA-Induced neural differentiation of human
NT2/D1 cells. J Neurosci Res. 90:2362–2377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oz S, Maercker C and Breiling A: Embryonic
carcinoma cells show specific dielectric resistance profiles during
induced differentiation. PLoS One. 8:e598952013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Musch T, Oz Y, Lyko F and Breiling A:
Nucleoside drugs induce cellular differentiation by
caspase-dependent degradation of stem cell factors. PLoS One.
5:e107262010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tripathi R, Samadder T, Gupta S, Surolia A
and Shaha C: Anticancer activity of a combination of cisplatin and
fisetin in embryonal carcinoma cells and xenograft tumors. Mol
Cancer Ther. 10:255–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang KS: Down-regulation of c-Ki-ras2
gene expression associated with morphologic differentiation in
human embryonal carcinoma cells treated with berberine. J Formos
Med Assoc. 90:10–14. 1991.
|
|
11
|
Skladchikova G, Berezin V and Bock E:
Valproic acid, but not its non-teratogenic analogue
2-isopropylpentanoic acid, affects proliferation, viability and
neuronal differentiation of the human teratocarcinoma cell line
NTera-2. Neurotoxicology. 19:357–370. 1998.PubMed/NCBI
|
|
12
|
Kakhki SA, Shahhoseini M and Salekdeh GH:
Comparative SRY incorporation on the regulatory regions of
pluripotency/differentiation genes in human embryonic carcinoma
cells after retinoic acid induction. Mol Cell Biochem. 376:145–150.
2013. View Article : Google Scholar
|
|
13
|
Megiorni F, Mora B, Indovina P and
Mazzilli MC: Expression of neuronal markers during NTera2/cloneD1
differentiation by cell aggregation method. Neurosci Lett.
373:105–109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jain P, Cerone MA, Leblanc AC and Autexier
C: Telomerase and neuronal marker status of differentiated NT2 and
SK-N-SH human neuronal cells and primary human neurons. J Neurosci
Res. 85:83–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheung WM, Fu WY, Hui WS and Ip NY:
Production of human CNS neurons from embryonal carcinoma cells
using a cell aggregation method. Biotechniques. 26:946–954.
1999.PubMed/NCBI
|
|
16
|
Snow GE, Kasper AC, Busch AM, et al: Wnt
pathway reprogramming during human embryonal carcinoma
differentiation and potential for therapeutic targeting. BMC
Cancer. 9:3832009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tegenge MA and Bicker G: Nitric oxide and
cGMP signal transduction positively regulates the motility of human
neuronal precursor (NT2) cells. J Neurochem. 110:1828–1841. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ardelt W, Ardelt B and Darzynkiewicz Z:
Ribonucleases as potential modalities in anticancer therapy. Eur J
Pharmacol. 625:181–189. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang CH, Gupta P, Michel R, et al:
Ranpirnase (frog RNase) targeted with a humanized, internalizing,
anti-Trop-2 antibody has potent cytotoxicity against diverse
epithelial cancer cells. Mol Cancer Ther. 9:2276–2286. 2010.
View Article : Google Scholar
|
|
20
|
Fang EF and Ng TB: Ribonucleases of
different origins with a wide spectrum of medicinal applications.
Biochim Biophys Acta. 1815:65–74. 2011.PubMed/NCBI
|
|
21
|
Zwolinska M and Smolewski P: Onconase: a
ribonuclease with antitumor activity. Postepy Hig Med Dosw
(Online). 64:58–66. 2010.(In Polish).
|
|
22
|
Chang CF, Chen C, Chen YC, Hom K, Huang RF
and Huang TH: The solution structure of a cytotoxic ribonuclease
from the oocytes of Rana catesbeiana (bullfrog). J Mol Biol.
283:231–244. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gahl RF, Narayan M, Xu G and Scheraga HA:
Dissimilarity in the oxidative folding of onconase and ribonuclease
A, two structural homologues. Protein Eng Des Sel. 21:223–231.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gahl RF and Scheraga HA: Oxidative folding
pathway of onconase, a ribonuclease homologue: insight into
oxidative folding mechanisms from a study of two homologues.
Biochemistry. 48:2740–2751. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rosenberg HF, Zhang J, Liao YD and Dyer
KD: Rapid diversification of RNase A superfamily ribonucleases from
the bullfrog, Rana catesbeiana. J Mol Evol. 53:31–38.
2001.PubMed/NCBI
|
|
26
|
Ita M, Halicka HD, Tanaka T, et al:
Remarkable enhancement of cytotoxicity of onconase and
cepharanthine when used in combination on various tumor cell lines.
Cancer Biol Ther. 7:1104–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee I: Ranpirnase (Onconase), a cytotoxic
amphibian ribonuclease, manipulates tumour physiological parameters
as a selective killer and a potential enhancer for chemotherapy and
radiation in cancer therapy. Expert Opin Biol Ther. 8:813–827.
2008. View Article : Google Scholar
|
|
28
|
Hu CC, Lee YH, Tang CH, Cheng JT and Wang
JJ: Synergistic cytotoxicity of Rana catesbeiana
ribonuclease and IFN-γ on hepatoma cells. Biochem Biophys Res
Commun. 280:1229–1236. 2001.PubMed/NCBI
|
|
29
|
Liao YD, Huang HC, Leu YJ, Wei CW, Tang PC
and Wang SC: Purification and cloning of cytotoxic ribonucleases
from Rana catesbeiana (bullfrog). Nucleic Acids Res.
28:4097–4104. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yiang GT, Yu YL, Chou PL, et al: The
cytotoxic protein can induce autophagocytosis in addition to
apoptosis in MCF-7 human breast cancer cells. In Vivo. 26:403–409.
2012.PubMed/NCBI
|
|
31
|
Wei CW, Hu CC, Tang CH, Lee MC and Wang
JJ: Induction of differentiation rescues HL-60 cells from Rana
catesbeiana ribonuclease-induced cell death. FEBS Lett.
531:421–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Costanzi J, Sidransky D, Navon A and
Goldsweig H: Ribonucleases as a novel pro-apoptotic anticancer
strategy: review of the preclinical and clinical data for
ranpirnase. Cancer Invest. 23:643–650. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mikulski S, Grossman A, Carter P, Shogen K
and Costanzi J: Phase I human clinical trial of
ONCONASE®* (P-30 protein) administered intravenously on
a weekly schedule in cancer patients with solid tumors. Int J
Oncol. 3:57–64. 1993.PubMed/NCBI
|
|
34
|
Mikulski SM, Costanzi JJ, Vogelzang NJ, et
al: Phase II trial of a single weekly intravenous dose of
ranpirnase in patients with unresectable malignant mesothelioma. J
Clin Oncol. 20:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vogelzang NJ, Aklilu M, Stadler WM, Dumas
MC and Mikulski SM: A phase II trial of weekly intravenous
ranpirnase (Onconase), a novel ribonuclease in patients with
metastatic kidney cancer. Invest New Drugs. 19:255–260. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang CH, Hu CC, Wei CW and Wang JJ:
Synergism of Rana catesbeiana ribonuclease and IFN-γ
triggers distinct death machineries in different human cancer
cells. FEBS Lett. 579:265–270. 2005.PubMed/NCBI
|
|
37
|
Tseng HH, Yu YL, Chen YL, et al:
RC-RNase-induced cell death in estrogen receptor positive breast
tumors through downregulation of Bcl-2 and estrogen receptor. Oncol
Rep. 25:849–853. 2011.PubMed/NCBI
|
|
38
|
Grabarek J, Ardelt B, Du L and
Darzynkiewicz Z: Activation of caspases and serine proteases during
apoptosis induced by onconase (Ranpirnase). Exp Cell Res.
278:61–71. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Halicka HD, Ardelt B, Shogen K and
Darzynkiewicz Z: Mild hyperthermia predisposes tumor cells to
undergo apoptosis upon treatment with onconase. Int J Oncol.
30:841–847. 2007.PubMed/NCBI
|
|
40
|
Michaelis M, Cinatl J, Anand P, et al:
Onconase induces caspase-independent cell death in chemoresistant
neuroblastoma cells. Cancer Lett. 250:107–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ramos-Nino ME, Vianale G, Sabo-Attwood T,
et al: Human mesothelioma cells exhibit tumor cell-specific
differences in phosphatidylinositol 3-kinase/AKT activity that
predict the efficacy of Onconase. Mol Cancer Ther. 4:835–842. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iordanov MS, Wong J, Newton DL, et al:
Differential requirement for the stress-activated protein
kinase/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis
in primary and in immortalized fibroblasts. Mol Cell Biol Res
Commun. 4:122–128. 2000. View Article : Google Scholar
|
|
43
|
Altomare DA, Rybak SM, Pei J, et al:
Onconase responsive genes in human mesothelioma cells: implications
for an RNA damaging therapeutic agent. BMC Cancer. 10:342010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yiang GT, Yu YL, Hu SC, Chen MH, Wang JJ
and Wei CW: PKC and MEK pathways inhibit caspase-9/-3-mediated
cytotoxicity in differentiated cells. FEBS Lett. 582:881–885. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wei CW, Chou PL, Hung YT and Yiang GT:
Synergistic cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea
and Rana catesbeiana ribonuclease-6 in hepatoma cells. Tzu
Chi Med J. 23:9–15. 2011. View Article : Google Scholar
|
|
46
|
Hu Z, Gu Y, Han B, et al: Knockdown of
AGR2 induces cellular senescence in prostate cancer cells.
Carcinogenesis. 33:1178–1186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Giovannini C, Gramantieri L, Minguzzi M,
et al: CDKN1C/P57 is regulated by the Notch target gene Hes1
and induces senescence in human hepatocellular carcinoma. Am J
Pathol. 181:413–422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leontieva OV, Natarajan V, Demidenko ZN,
Burdelya LG, Gudkov AV and Blagosklonny MV: Hypoxia suppresses
conversion from proliferative arrest to cellular senescence. Proc
Natl Acad Sci USA. 109:13314–13318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ewald JA, Desotelle JA, Church DR, et al:
Androgen deprivation induces senescence characteristics in prostate
cancer cells in vitro and in vivo. Prostate. 73:337–345. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Burns TF, Dobromilskaya I, Murphy SC, et
al: Inhibition of TWIST1 leads to activation of oncogene-induced
senescence in oncogene-driven non-small cell lung cancer. Mol
Cancer Res. 11:329–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tu Z, Zhuang X, Yao YG and Zhang R: BRG1
is required for formation of senescence-associated heterochromatin
foci induced by oncogenic RAS or BRCA1 loss. Mol Cell Biol.
33:1819–1829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Capparelli C, Chiavarina B,
Whitaker-Menezes D, et al: CDK inhibitors (p16/p19/p21) induce
senescence and autophagy in cancer-associated fibroblasts,
‘fueling’ tumor growth via paracrine interactions, without an
increase in neo-angiogenesis. Cell Cycle. 11:3599–3610.
2012.PubMed/NCBI
|
|
53
|
Wu X, Jia S, Zhang X, Si X, Tang W and Luo
Y: Two mechanisms underlying the loss of p16Ink4a
function are associated with distinct tumorigenic consequences for
WS MEFs escaping from senescence. Mech Ageing Dev. 133:549–555.
2012.PubMed/NCBI
|
|
54
|
Iordanov MS, Ryabinina OP, Wong J, et al:
Molecular determinants of apoptosis induced by the cytotoxic
ribonuclease onconase: evidence for cytotoxic mechanisms different
from inhibition of protein synthesis. Cancer Res. 60:1983–1994.
2000.
|
|
55
|
Kvissel AK, Orstavik S, Oistad P, Rootwelt
T, Jahnsen T and Skalhegg BS: Induction of Cβ splice variants and
formation of novel forms of protein kinase A type II holoenzymes
during retinoic acid-induced differentiation of human NT2 cells.
Cell Signal. 16:577–587. 2004.
|
|
56
|
Patel NA, Song SS and Cooper DR: PKCδ
alternatively spliced isoforms modulate cellular apoptosis in
retinoic acid-induced differentiation of human NT2 cells and mouse
embryonic stem cells. Gene Expr. 13:73–84. 2006.
|
|
57
|
Misiuta IE, Saporta S, Sanberg PR, Zigova
T and Willing AE: Influence of retinoic acid and lithium on
proliferation and dopaminergic potential of human NT2 cells. J
Neurosci Res. 83:668–679. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pistritto G, Papaleo V, Sanchez P, Ceci C
and Barbaccia ML: Divergent modulation of neuronal differentiation
by caspase-2 and −9. PLoS One. 7:e360022012.PubMed/NCBI
|
|
59
|
Zhang XP, Zhang GH, Wang YY, et al:
Oxidized low-density lipoprotein induces hematopoietic stem cell
senescence. Cell Biol Int. 37:940–948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Carracedo J, Buendia P, Merino A, et al:
Cellular senescence determines endothelial cell damage induced by
uremia. Exp Gerontol. 48:766–773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim HD, Yu SJ, Kim HS, et al: IL-4 induces
senescence in human renal carcinoma cell lines through STAT6 and
p38 MAPK. J Biol Chem. 288:28743–28754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Luo H, Yount C, Lang H, et al: Activation
of p53 with Nutlin-3a radiosensitizes lung cancer cells via
enhancing radiation-induced premature senescence. Lung Cancer.
81:167–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Suo R, Zhao ZZ, Tang ZH, et al: Hydrogen
sulfide prevents H2O2-induced senescence in
human umbilical vein endothelial cells through SIRT1 activation.
Mol Med Rep. 7:1865–1870. 2013.PubMed/NCBI
|
|
64
|
Mo J, Sun B, Zhao X, et al:
Hypoxia-induced senescence contributes to the regulation of
microenvironment in melanomas. Pathol Res Pract. 209:640–647. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bassaneze V, Miyakawa AA and Krieger JE:
Chemiluminescent detection of senescence-associated β
galactosidase. Methods Mol Biol. 965:157–163. 2013.PubMed/NCBI
|
|
66
|
Pospelova TV, Chitikova ZV and Pospelov
VA: An integrated approach for monitoring cell senescence. Methods
Mol Biol. 965:383–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mortuza R, Chen S, Feng B, Sen S and
Chakrabarti S: High glucose induced alteration of SIRTs in
endothelial cells causes rapid aging in a p300 and FOXO regulated
pathway. PLoS One. 8:e545142013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Diep CH, Charles NJ, Gilks CB, Kalloger
SE, Argenta PA and Lange CA: Progesterone receptors induce
FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle.
12:1433–1449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang H, Xu Y, Fang Z, Chen S, Balk SP and
Yuan X: Doxycycline regulated induction of AKT in murine prostate
drives proliferation independently of p27 cyclin dependent kinase
inhibitor downregulation. PLoS One. 7:e413302012. View Article : Google Scholar
|
